Pruvanserin

Last updated
Pruvanserin
Pruvanserin.png
Clinical data
Other namesEMD-281,014; EMD-281014; LY-2422347; LY2422347; LSN2411347; LSN-2411347
Routes of
administration 		Oral [1]
Drug class Serotonin 5-HT2A receptor antagonist
ATC code
  • None
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
Onset of action Tmax Tooltip Time to peak levels: 2–3 hours (range 2–6 hours) [2]
Elimination half-life 8.6–9.5 hours (range 3.9–12.4 hours) [2]
Identifiers
  • 7-[4-[2-(4-fluorophenyl)ethyl]piperazine-1-carbonyl]-1H-indole-3-carbonitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C22H21FN4O
Molar mass 376.435 g·mol−1
3D model (JSmol)
  • C1CN(CCN1CCC2=CC=C(C=C2)F)C(=O)C3=CC=CC4=C3NC=C4C#N
  • InChI=1S/C22H21FN4O/c23-18-6-4-16(5-7-18)8-9-26-10-12-27(13-11-26)22(28)20-3-1-2-19-17(14-24)15-25-21(19)20/h1-7,15,25H,8-13H2
  • Key:AQRLDDAFYYAIJP-UHFFFAOYSA-N

Pruvanserin (INN Tooltip International Nonproprietary Name; USAN Tooltip United States Adopted Name; developmental code names EMD-281,014, LY-2422347) is a selective serotonin 5-HT2A receptor antagonist which was under development by Eli Lilly and Company for the treatment of insomnia. [1] [3] [4] It was in phase II clinical trials in 2008 but appears to have been discontinued as it is no longer in the company's development pipeline. [5] [6]

Contents

Pharmacology

Pharmacodynamics

Pruvanserin acts as a selective serotonin 5-HT2A receptor antagonist. In addition to its sleep-improving properties, [7] [8] pruvanserin has also been shown to have antidepressant, anxiolytic, and working memory-enhancing effects in animal studies. [9] [10] [11]

Pharmacodynamics

The time to peak levels of pruvanserin is 2 to 3 hours, with a range of 2 to 6 hours. [2] The mean elimination half-life of pruvanserin is 8.6 to 9.5 hours, with a range of 3.9 to 12.4 hours. [2] However, its brain serotonin 5-HT2A receptor occupancy lasts much longer, with a half-life of approximately 24 hours. [2]

See also

References

  1. 1 2 "Pruvanserin". AdisInsight. 19 August 2014. Retrieved 16 January 2026.
  2. 1 2 3 4 5 Mamo D, Sedman E, Tillner J, Sellers EM, Romach MK, Kapur S (September 2004). "EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study". Psychopharmacology (Berl). 175 (3): 382–388. doi:10.1007/s00213-004-1817-7. PMID   15007535.
  3. ↑ Bartoszyk GD, van Amsterdam C, Böttcher H, Seyfried CA (July 2003). "EMD 281014, a new selective serotonin 5-HT2A receptor antagonist". European Journal of Pharmacology. 473 (2–3): 229–30. doi:10.1016/S0014-2999(03)01992-7. PMID   12892843.
  4. ↑ Teegarden BR, Al Shamma H, Xiong Y (2008). "5-HT(2A) inverse-agonists for the treatment of insomnia". Current Topics in Medicinal Chemistry. 8 (11): 969–76. doi:10.2174/156802608784936700. PMID   18673166.
  5. ↑ "Efficacy Study of LY2422347 to Treat Insomnia - Full Text View - ClinicalTrials.gov". 24 January 2007.
  6. ↑ "Eli Lilly and Company » Research Pipeline".
  7. ↑ Monti JM, Jantos H (September 2006). "Effects of activation and blockade of 5-HT2A/2C receptors in the dorsal raphe nucleus on sleep and waking in the rat". Progress in Neuro-psychopharmacology & Biological Psychiatry. 30 (7): 1189–95. doi:10.1016/j.pnpbp.2006.02.013. PMID   16713054. S2CID   12837755.
  8. ↑ Monti JM, Jantos H (December 2006). "Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat". European Journal of Pharmacology. 553 (1–3): 163–70. doi:10.1016/j.ejphar.2006.09.027. PMID   17059817.
  9. ↑ Patel JG, Bartoszyk GD, Edwards E, Ashby CR (April 2004). "The highly selective 5-hydroxytryptamine (5-HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test". Synapse. 52 (1): 73–5. doi:10.1002/syn.10308. PMID   14755634. S2CID   21941333.
  10. ↑ Adamec R, Creamer K, Bartoszyk GD, Burton P (November 2004). "Prophylactic and therapeutic effects of acute systemic injections of EMD 281014, a selective serotonin 2A receptor antagonist on anxiety induced by predator stress in rats". European Journal of Pharmacology. 504 (1–2): 79–96. doi:10.1016/j.ejphar.2004.09.017. PMID   15507224.
  11. ↑ Terry AV, Buccafusco JJ, Bartoszyk GD (June 2005). "Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys". Psychopharmacology. 179 (4): 725–32. doi:10.1007/s00213-004-2114-1. PMID   15619109. S2CID   30366683.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.